论文部分内容阅读
目的:本文主要探讨对于使用头孢地尼治疗呼吸道感染症状的临床效果以及其安全性。方法:选择我院2010年1月至2013年1月期间治疗的100例呼吸道感染症状患者,全部病例经过对血和尿常规进行检查以及开展痰细菌的培养、药敏试验等确诊为呼吸道感染。对所有患者使用100mg的头孢地尼胶囊,每天服用3次,连续口服用药7天后,对患者开展随访,对患者的呼吸道感染一些症状和体征进行记录并开展评价,对不良反应同时作出记录。结果:100例患者全部采用头孢地尼胶囊治疗,通过随访观察,经过治疗后,患者的症状得到明显的改善,使用头孢地尼对呼吸道感染症状进行治疗的总有效率达到92%,对于社区获得性肺炎和慢支急性发作以及急性细茵性的支气管炎有效率较高,为90%、82%和95%,没有发生较为严重的不良反应。结论:通过分析可知使用头孢地尼对呼吸道感染疾病进行治疗是安全的且有效的。
Objectives: This article focuses on the clinical efficacy of cefdinir in the treatment of respiratory tract infections and their safety. Methods: A total of 100 patients with respiratory tract infection who were treated in our hospital from January 2010 to January 2013 were selected. All patients were diagnosed as respiratory tract infection by blood and urine routine examination, sputum bacterial culture and drug sensitivity test. 100 mg of cefdinir capsules were administered to all patients three times a day for 7 days after continuous oral administration. Patients were followed up and some symptoms and signs of respiratory infections were recorded and evaluated. Adverse reactions were also recorded. Results: All 100 patients were treated with cefdinir capsules. After follow-up observation, the symptoms of patients were significantly improved after treatment. The total effective rate of using cefdinir to treat respiratory symptoms was 92%. For community-acquired Acute pneumonia and chronic bronchitis and acute genital bronchitis have a higher efficiency of 90%, 82% and 95%, no more serious adverse reactions. Conclusions: It is safe and effective to use cefdinir for the treatment of respiratory tract infections through analysis.